000 | 05052cam a2200685Ii 4500 | ||
---|---|---|---|
001 | 9780429155826 | ||
003 | FlBoTFG | ||
005 | 20220531132352.0 | ||
006 | m o d | ||
007 | cr cnu|||unuuu | ||
008 | 190618t20202020flu ob 001 0 eng d | ||
040 |
_aOCoLC-P _beng _erda _epn _cOCoLC-P |
||
020 |
_a9780429155826 _q(electronic bk.) |
||
020 |
_a0429155824 _q(electronic bk.) |
||
020 |
_a9780429546549 _q(electronic bk. : Mobipocket) |
||
020 |
_a0429546548 _q(electronic bk. : Mobipocket) |
||
020 |
_a9781498761314 _q(electronic bk. : PDF) |
||
020 |
_a1498761313 _q(electronic bk. : PDF) |
||
020 |
_a9780429531842 _q(electronic bk. : EPUB) |
||
020 |
_a0429531842 _q(electronic bk. : EPUB) |
||
020 | _z9781498761307 | ||
035 | _a(OCoLC)1104836029 | ||
035 | _a(OCoLC-P)1104836029 | ||
050 | 4 | _aRC270.8 | |
072 | 7 |
_aHEA _x039000 _2bisacsh |
|
072 | 7 |
_aMED _x014000 _2bisacsh |
|
072 | 7 |
_aMED _x022000 _2bisacsh |
|
072 | 7 |
_aMED _x112000 _2bisacsh |
|
072 | 7 |
_aMED _x045000 _2bisacsh |
|
072 | 7 |
_aMAT _x029000 _2bisacsh |
|
072 | 7 |
_aMED _x028000 _2bisacsh |
|
072 | 7 |
_aMED _x071000 _2bisacsh |
|
072 | 7 |
_aMBNS _2bicssc |
|
082 | 0 | 4 |
_a616.99406 _223 |
100 | 1 |
_aKhan, Iftekhar _c(Statistician), _eauthor. |
|
245 | 1 | 0 |
_aEconomic evaluation of cancer drugs : _busing clinical trial and real-world data / _cIftekhar Khan, Ralph Crott, and Zahid Bashir. |
264 | 1 |
_aBoca Raton : _bCRC Press, _c[2020] |
|
264 | 4 | _c©2020 | |
300 | _a1 online resource. | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
490 | 1 | _aChapman & Hall/CRC biostatistics series | |
520 | _aCancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission. | ||
588 | _aOCLC-licensed vendor bibliographic record. | ||
650 | 0 |
_aCancer _xTreatment _xEconomic aspects. |
|
650 | 0 | _aPharmaceutical industry. | |
650 | 7 |
_aHEALTH & FITNESS / Diseases / General. _2bisacsh |
|
650 | 7 |
_aMEDICAL / Clinical Medicine. _2bisacsh |
|
650 | 7 |
_aMEDICAL / Diseases. _2bisacsh |
|
650 | 7 |
_aMEDICAL / Evidence-Based Medicine. _2bisacsh |
|
650 | 7 |
_aMEDICAL / Internal Medicine. _2bisacsh |
|
650 | 7 |
_aMATHEMATICS / Probability & Statistics / General _2bisacsh |
|
650 | 7 |
_aMEDICAL / Epidemiology _2bisacsh |
|
650 | 7 |
_aMEDICAL / Pharmacology _2bisacsh |
|
700 | 1 |
_aCrott, Ralph, _eauthor. |
|
700 | 1 |
_aBashir, Zahid, _eauthor. |
|
856 | 4 | 0 |
_3Taylor & Francis _uhttps://www.taylorfrancis.com/books/9780429155826 |
856 | 4 | 2 |
_3OCLC metadata license agreement _uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf |
999 |
_c71396 _d71396 |